Jun 54 minDragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results
Dec 8, 20222 minDragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKETâ„¢
Nov 1, 20222 minDragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target
May 1, 20221 minGilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engage
Mar 1, 20221 minBristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat
Nov 23, 20212 minDragonfly Therapeutics Announces Merck Opt-In of TriNKETâ„¢ Immunotherapy Candidate for Patients
Nov 9, 20213 minDragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer